Paul Basciano
Research Subjects
Paul Basciano has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Arielle Yablonovitch
Guardant Health, Palo Alto, California
11 shared publications - Benedito Arruda Carneiro
Legorreta Cancer Center, Brown University, Providence, RI 02912, USA
11 shared publications - Benjamin Herzberg
Division of Hematology and Oncology, Columbia University Irving Medical Center , New York, NY 10032
11 shared publications - Danielle Ulanet
Repare Therapeutics, Cambridge, Massachusetts
11 shared publications - Elisa Fontana
Sarah Cannon Research Institute UK, London, United Kingdom
11 shared publications - Elizabeth K. Lee
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
11 shared publications
Latest Publications
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
CtDNA-based enrollment PV detection and allelic status calls.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
CtDNA-based enrollment PV detection and allelic status calls.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
CHRD scores based on tumor type, genotype and tumor or ctDNA-derived allelic status.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
CHRD scores based on tumor type, genotype and tumor or ctDNA-derived allelic status.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
Details of reversion alterations in reversion evaluable patients
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
Details of reversion alterations in reversion evaluable patients
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
IGV screenshots for two patients with ATM reversions.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
IGV screenshots for two patients with ATM reversions.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
A, b) Lollipop plot of the a) TP53BP1 and b) RIF1 mutations identified in a patient with BRCA1-altered pancreatic cancer.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
A, b) Lollipop plot of the a) TP53BP1 and b) RIF1 mutations identified in a patient with BRCA1-altered pancreatic cancer.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
Relationship between genomic and epigenomic measures of tumor fraction.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
Relationship between genomic and epigenomic measures of tumor fraction.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
Relationship between TF measures and clinical disease burden.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
Relationship between TF measures and clinical disease burden.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
Reversion detection by clinical and genomic characteristics.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
Reversion detection by clinical and genomic characteristics.